November 2015

Although there often is controversy over the impact of new cancer drugs on patients’ overall survival, there can be little argument over the broad improvements that have flowed from more than four decades of investment in oncology research.

With scores of subtypes and a paucity of molecular markers, soft tissue sarcoma remains a complex and challenging tumor type to treat yet significant strides being made in the field are likely to alter the therapeutic paradigm.

Mark C. Capone discusses the challenges and opportunities in molecular diagnostics, and what's ahead at Myriad Genetics.

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.

Kenneth C. Anderson, MD, has helped transform multiple myeloma from an essentially untreatable disease to a chronic condition. He was honored in the Myeloma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group has launched to honor leaders in the field.

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

Particular progress has been made in the development of small-molecule inhibitors of key signaling pathways that are responsible for the unique characteristics of stem cells, developed by biotechnology companies focused solely on CSC-targeting therapies.

As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions.

The goal of increasing communications with the patient about all available and useful therapies contributes to better care of individuals and allows for continued education from oncology providers on potential risks and benefits of such therapies.

In some ways, the Pathway Genomics test reflects the serious problem of lead time bias in the oncology arena.